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Abstract Objective To evaluate, among new users of
inhaled corticosteroids that did not persist treatment,
knowledge of inhaled corticosteroids’ actions and whether
they were instructed on the use of their inhaler. Setting
Fifteen community pharmacies in The Netherlands. Meth-
ods Patients were interviewed by telephone. Their general
practitioners provided diagnostic information and auto-
mated dispensing records were retrieved. Main outcome
measuresKnowledgeofpatientsabouttheactionsofinhaled
corticosteroids. Results 230 (80.1%) of 287 patients were
willing to participate. The majority (79.1%) of 230 patients
was not aware of the anti-inﬂammatory actions of inhaled
corticosteroids. Most patients were instructed on the use of
their inhaler, predominantly by their physician (53%) or
pharmacy (35.2%). Conclusions Although most patients
reported inhaler instruction by at least one health care pro-
vider, the majority was unaware of inhaled corticosteroids’
actions. Physicians and pharmacists should reconsider the
instructions they provide especially to patients who should
continuously use inhaled corticosteroids.
Keywords Asthma  Community pharmacy 
Discontinuing treatment  Disease control  Inhaled
corticosteroids  Knowledge of drugs  Netherlands
Impact of ﬁndings on practice
• The majority of new users of inhaled corticosteroids
(ICS) who did not persist treatment were unaware of
ICS’ anti inﬂammatory actions.
• Physicians and pharmacists should reconsider the
instructions they provide to patients who should
continuously use ICS.
Introduction
Educating patients on the self-management and thus on
actions and correct use of their medication is a fundamental
component of asthma management guidelines [1]. Studies
on continuous use of inhaled corticosteroids (ICS), showed
low persistence and adherence rates varying from 17 to
60% [2–5]. Persistence is generally even lower among new
users [6–8]. It has also been shown that patients who do not
regularly use ICS, have poor asthma control [9, 10].
In general, non-adherence is associated with a lack of
patients’ knowledge about the disease and treatment [7, 11–
13]. Studies among patients starting new medication for
chronic conditions show that most patients frequently
experiencepractical difﬁcultieswithtakingtheirmedication
[7, 14]. However, these studies did not include patients with
respiratory conditions or those who were prescribed ICS.
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new users could be related to inadequate instructions of
patients about the anti-inﬂammatory properties of ICS and
the potential preventive effect of chronic ICS treatment on
the occurrence and severity of exacerbations.
Aim of the study
The aim of the present study was to evaluate the knowledge
of ICS actions, among new users of ICS that discontinued
treatment. Additionally we aimed to identify which factors
inﬂuenced knowledge about ICS.
Method
Study design
A cross-sectional study in community pharmacies in The
Netherlands. Fifteen pharmacies from three clusters of
pharmacies both in highly urban areas, in urban and rural
areas were included.
Participants
New ICS users were deﬁned as patients who did not ﬁll an
ICS prescription in the 2 years before a ﬁrst ICS pre-
scription. Early discontinuation was deﬁned as the absence
of an ICS reﬁll within at least 6 months after this ﬁrst
prescription. In The Netherlands patients are allowed to be
dispensed a supply of canisters sufﬁcient for a maximum
period of 3 months. Consequently, we determined discon-
tinuing of ICS after a grace period of 3 months, a total
period of 6 months. The majority of patients in The
Netherlands visit the same community pharmacy, inde-
pendently of prescriber. Pharmacy records are therefore
virtually complete with regard to prescription drugs [15].
Procedure
Patients were contacted by telephone by their pharmacist.
For patients that could not be contacted during pharmacy
opening hours, at least one new attempt was made in
evening hours. The telephone interview was conducted
using a structured questionnaire. For patients aged less than
14 years, the patients’ caregiver was interviewed.
The general practitioner (GP) of eligible patients were
asked to provide information on the diagnosis as well as on
the severity of symptoms using a questionnaire. To reduce
GPs workload, each GP was asked to provide the infor-
mation of a maximum of randomly selected 20 patients.
Privacy
The research was conducted in accordance with the
requirements of the Institutional Review Board (IRB).
According to the IRB informed consent was not required.
The questionnaires were anonymised by use of a randomly
assigned unique number for each patient. During the
interview, patients were speciﬁcally asked for their consent
to use the data anonymously for research purposes.
Questionnaires
Questionnaire for patient interview
One questionnaire referred to knowledge of the inhalers’
action and on the health care providers that actually
instructed the patient on the use of the inhaler. Questions
were asked by means of open-ended questions. The
answers were coded by the researchers. In this respect we
were relatively forgiving e.g. when patients mentioned an
ICS was a preventer we coded this as proper knowledge
although they did not speciﬁcally call it a corticosteroid or
antiinﬂammatory drug. In addition, a 6-item version of the
Asthma Control Questionnaire (ACQ; without FEV1) was
used to assess disease control. An ACQ score of 1.5 or
higher was regarded as possibly not well-controlled disease
[16].
GP questionnaire
The questionnaire for the GPs comprised questions on
diagnosis, disease severity and whether patients should
have continued ICS use.
Statistical analysis
Descriptive statistics were calculated for selected patients.
Conditional logistic regression was applied to analyse the
association between adequate ICS knowledge and poten-
tially confounding variables. P\0.05 was considered
statistically signiﬁcant.
Results
Baseline characteristics of responders
Within the 15 participating community pharmacies 287
(42.4%) out of 677 new ICS users did not reﬁll any ICS
prescription within 6 months after the ﬁrst ICS prescrip-
tion. Out of these 287 eligible patients, pharmacists inter-
viewed 230 (80.1%).
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gender and medication use between 230 patients inter-
viewed and 57 patients not participating.
About half the sample (49.1%) was older than 45 years.
The majority of the patients (65.7%) received at least one
prescription for any bronchodilator in the year preceding
the survey.
Inhalation instruction
The majority of the patients (53%) recalled to have been
instructed either by their prescriber or by their pharmacist
(35.2%) (Table 1). 35.2 of patients from each pharmacy
claimed to have been instructed by their pharmacist. The
percentage varied from 0 to 91% between pharmacies.
Knowledge of ICS
A substantial part of patients (44.3%) was unable to men-
tion the effects of ICS. A minority (14.3%) stated that the
effect of ICS was anti-inﬂammatory. Fifteen patients
(6.5%) attributed both bronchodilating and anti-inﬂamma-
tory effects to ICS (6 of these patients used an inhaler
containing a combination of both an ICS and bronchodi-
lator) (Table 1). Patients may perceive that an anti-
inﬂammatory effect will also lead to bronchodilation.
Therefore, these patients were also considered to have
adequate knowledge. In total, 79.1% patients were giving
incorrect answers.
Patientswhowereawareoftheanti-inﬂammatoryactions
ofICSwereyounger (OR0.98[0.96–0.99])andtendedtobe
more often female (OR 1.6 [0.9–3.6]) (Table 2). There was
no association between patients’ self reported symptoms
(measured by the ACQ) or concomitant use of bronchodi-
lators and knowledge of ICS’ actions. Self reported
instruction either by physician, pharmacy or both did not
seem to affect patients knowledge of ICS’ actions (Table 2).
Asthma diagnosis and disease severity according to GP
Twenty-one of 40 GPs were willing to participate in the
study. Consequently, questionnaires on diagnosis and
symptom severity of 115 of the 230 participating patients
were received. Physicians suspected 67 (58.3%) patients of
having asthma. Twelve (11.2%) of these patients had not
well-controlled asthma. According to the GPs, 28 patients
should not have discontinued ICS treatment.
Of these 115 patients, 88 (76.5%) were not aware of the
anti-inﬂammatory effects of ICS. There was no association
between suspicion of asthma by the GP and knowledge of
ICS.Exceptage,noneoftheotherdeterminantsstudied,was
signiﬁcantly associated with unawareness of ICS actions
(Table 2).
Discussion
This study shows that the majority of patients who early
discontinued the use of ICS lacked knowledge about the
potential anti-inﬂammatory effects of ICS. Patients who
were aware of the anti-inﬂammatory actions of ICS were
younger and tended to be more frequently female. Age and
gender differences in asthma knowledge have been repor-
ted previously [17, 18].
Knowledge of the anti-inﬂammatory actions of ICS was
not inﬂuenced by either an asthma diagnosis or the expe-
rience of symptoms measured by the ACQ.
Recall bias may be a limitation of the study, as at least
6 months elapsed between the telephone interview and the
index ICS prescription. However, most patients did not opt
that they could not recollect the answer to our questions.
Patients may be aware of ICS actions, but not able to put
them into words by themselves, and they may be inﬂuenced
by response categories. Hence the conclusions about
patient awareness will depend on the interview method.
As the study does not compare with patients who con-
tinue their treatment, the study has no possibility of deter-
mining to what extent lack of knowledge on ICS actions can
explain discontinuation. You might ﬁnd the same lack of
Table 1 Demographic characteristics, questionnaire items and med-
ication use for the total population
Total 230
patients
(100%)
Gender (% female) 139 (60.4%)
Average age(±SD) 46.3 (±25.5)
ACQ-score
a
\1.5 (probably well controlled) 186 (80.9%)
C1.5 (probably not well controlled) 30 (13.0%)
Drug effects ascribed to ICS
Patient could not recall a clear mode of action 102 (44.3%)
Bronchodilatation 66 (28.7%)
Anti-inﬂammatory 33 (14.3%)
Bronchodilatation and anti-inﬂammatory 15 (6.5%)
Antitussive or mucolytic effect 14 (6.1%)
Inhalation instruction
Patient could not recall instruction 41 (17.8%)
Physician (GP or pulmonologist)
b 122 (53.0%)
Pharmacist
b 81 (35.2%)
GP assistant/nurse
b 10 (4.3%)
Only information leaﬂet 11 (4.8%)
a Excluding 14 patients with C1 missing item in the ACQ
b 35 patients (15.2%) received instruction by more than one health-
care provider
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123knowledge in persistent patients, which would lead to other
interpretations of the role of knowledge about ICS actions
in ICS persistence. Selection bias might also have occurred
as the response rate among GP’s was about 50%.
Nevertheless, the large proportion of patients with low
ACQ scores and without high use of bronchodilators sug-
gests that the majority of the patients might have discon-
tinued ICS appropriately. The initial indication for the use
of ICS might be partly off-label, such as cough. It is
therefore possible that, for these patients, the physician did
not consider it necessary to explain ICS’ actions. However
in the subgroup of patients with a conﬁrmed GP asthma
diagnosis, knowledge of ICS actions did not differ from
patients without an asthma diagnosis. Even patients of
whom the GP indicated that they should have continued
using ICS did not have more knowledge on ICS actions.
Apparently, instructions by health care providers are
mainly focused on inhalation technique, as almost all
patients claimed to be instructed by at least one health care
provider. Patients most frequently mentioned the physician
as their instructor of inhaler technique. One third of
patients stated that they were instructed by the pharmacy
on the use of the inhaler, somewhat higher than reported by
Mehuys and co-workers [19]. Nevertheless, there is sig-
niﬁcant opportunity to increase pharmacists’ instructions of
patients. This study showed that being instructed was not
associated with increased asthma knowledge. It is impor-
tant to move instruction beyond inhalation technique and
also address the purpose and importance of regular ICS
use. Information given to patients can be reinforced by
different health care providers [20]. As this study shows
that a considerable number of patients have less clear
indications for the use of ICS, physicians and pharmacists
need to cooperate to identify those patients that are most
likely to beneﬁt from monitoring and instructing.
Conclusion
Although most patients reported inhaler instruction by at
least one health care provider, the majority was unaware of
inhaled corticosteroids’ actions. Physicians and pharma-
cists should reconsider the instructions they provide espe-
cially to patients who should continuously use inhaled
corticosteroids.
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Table 2 Comparison of patients who were aware of anti-inﬂammatory actions of ICS and those who were not aware of anti-inﬂammatory
actions of ICS
Knowledge of
ICS’ actions
No knowledge
of ICS’ actions
Crude OR
OR (95% CI)
Adjusted OR
OR (95% CI)
Sample of patients interviewed by telephone (n = 230) n = 48 n = 182
Gender (% female) 33 (68.8%) 106 (58.2%) 1.6 (0.8–3.1) 1.9 (0.9–3.6)
a
Age, years mean ± SD 34.0 ± 19.7 44.7 ± 24.5 0.98 (0.97–0.99) 0.98 (0.96–0.99)
a
ACQ score, mean ± SD 0.67 ± 1.5 0.45 ± 1.0 1.3 (0.9–1.7) 1.2 (0.9–1.7)
a
Asthma according to patient 5 (10.4%) 17 (9.8%) 1.1 (0.4–3.0) –
Instruction
Physician 21 (43.8%) 101 (55.5%) 0.6 (0.3-1.2) –
Pharmacist 20 (41.7%) 61 (33.5%) 1.4 (0.7–2.7) 1.2 (0.6–2.4)
a
No verbal instruction 11 (22.9%) 40 (22.0%) 0.9 (0.4–2.0) –
Sample of patients of whom the GP was interviewed (n = 115*) n = 27 n = 88
Gender (% female) 19 (70.4%) 49 (55.7%) 1.9 (0.7–4.8) 2.7 (0.7–7.8)
b
Age, years mean ± SD 34.1 ± 21.5 46.3 ± 26.3 0.98 (0.96–1.0) 0.97 (0.94–0.99)
b
Diagnosis or suspicion of asthma 16 (59.3%) 51 (58.0%) 1.1 (0.4–2.5) 0.7 (0.2–2.3)
b
ICS intended for chronic use 6 (22.2%) 22 (25.0%) 0.9 (0.3–2.4) 1.3 (0.4–4.0)
b
* Twenty-one of 40 GPs were willing to participate in the study. In addition, each GP was asked to provide the information of a maximum of 20
patients. Therefore, the GP information was only available for 115 patients
a adjusted for all variables with more than 5 events per variable; replacing ‘pharmacist instruction’ by ‘GP instruction’ or ‘no instruction’ did not
change the model appreciably
b Additional adjustment for Asthma diagnosis and ICS intended as chronic medication
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